Unicycive Therapeutics Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Hi. Thank you so much for being part of Unicycive's presentation today, and thanks for giving this opportunity to wrap up. My name is Shalabh Gupta, Founder, Chairman, and CEO of the company. Unicycive is focused on novel treatments of kidney diseases. We have two drugs that are both in clinical programs right now, and I'll give you an overview of presentation and tell you what is so exciting to hear about Unicycive.
This is the forward-looking statement, which I'm not going to read. I'll caution you before considering any investment decisions to read this through and make your decision accordingly.
By way of background, our company is focused on two different drugs. Our lead drug is RENAZORB, which is indicated for treatment of high phosphate or also called hyperphosphatemia in patients who suffer from chronic kidney disease but towards the very end of the stage, which is called ESRD or end-stage renal disease. Our second drug is going through Phase 1 clinical trial, and it's indicated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
